Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Ascentage Pharma (NASDAQ: AAPG) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026. The team will appear in a fireside chat at 9:30 am ET on Thursday, February 12, 2026.
The live webcast can be accessed via the Events page in the company's Investor Relations website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AAPG was up 1.36% with peers mixed: some modest gains (e.g., one peer up 5.2%) and others down as much as 2%, suggesting stock-specific factors rather than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Strategy update | Positive | -3.6% | Outlined 2026 global innovation strategy and advancing multiple Phase III programs. |
| Jan 06 | Regulatory milestone | Positive | -3.5% | Announced U.S. FDA IND clearance for BTK degrader APG-3288 Phase I study. |
| Dec 17 | Conference participation | Neutral | -3.1% | Planned presentation at 44th J.P. Morgan Healthcare Conference for investor outreach. |
| Dec 08 | Clinical data update | Positive | -4.0% | Phase II olverembatinib data showed improved EFS and favorable safety in CML-CP. |
| Dec 08 | Clinical data update | Positive | -4.0% | ASH 2025 olverembatinib second-line CML-CP data with high CCyR and MMR rates. |
Across the last five news items, AAPG frequently traded lower (around -3% to -4%) after generally positive or neutral updates, indicating a pattern of weak price responses to favorable disclosures.
Over recent months, Ascentage Pharma has highlighted progress across its hematology and oncology portfolio. In December 2025 it reported strong olverembatinib efficacy and safety data at ASH and additional encouraging CML-CP results, yet shares fell about 4% on both days. Subsequent January 2026 updates on investor conference participation, global innovation strategy, and APG-3288 IND clearance in B‑cell malignancies also saw declines of roughly 3%–4%. Today’s Guggenheim summit participation fits this ongoing investor-relations visibility push.
Market Pulse Summary
This announcement highlights Ascentage Pharma’s ongoing engagement with the investment community via the Guggenheim Emerging Outlook: Biotech Summit 2026, including a fireside chat at 9:30 a.m. EST on February 12. It continues a series of conference appearances and updates following ASH 2025 data and APG-3288 IND clearances. With shares trading below the 200-day MA of 33.19 and well under the 52‑week high, investors may watch how consistent communication interacts with clinical and regulatory milestones.
AI-generated analysis. Not financial advice.
ROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 being held on February 11-12, 2026.
The management team will be participating in a fireside chat at 9:30 am EST on Thursday, February 12th. The webcast can be accessed by visiting the Events page in the Investor Relations section of Ascentage’s website.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.
The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Yuly Chen, Senior Investor Relations Director
Ascentage Pharma
IR@ascentage.com
+86 512 85557777
+1 (301) 792-5658
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ
When will Ascentage Pharma (AAPG) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?
How can investors access the Ascentage Pharma (AAPG) webcast for the Guggenheim Biotech Summit?
What will Ascentage Pharma (AAPG) management discuss at the fireside chat on February 12, 2026?
What are the dates and schedule details for Guggenheim Emerging Outlook: Biotech Summit 2026 relevant to AAPG?
Will the Ascentage Pharma (AAPG) fireside chat at Guggenheim 2026 be available after the live event?
